Nuwellis decoration

Newsroom

Newsroom

Press Releases

Date Title and Summary Additional Formats
August 9, 2022
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results
MINNEAPOLIS , Aug. 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022 , which included the following highlights: Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first
July 26, 2022
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid Overloaded Heart Failure Patients Resistant to Diuretics MINNEAPOLIS , July 26, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc.
July 14, 2022
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022
MINNEAPOLIS , July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 . The company will host a conference call and webcast at 9:00 AM ET , during which management will discuss the
July 12, 2022
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
MINNEAPOLIS , July 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded
June 29, 2022
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS , June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF
June 14, 2022
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
Pediatric Segment Growth Continues at 36% CAGR MINNEAPOLIS , June 14, 2022 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two
May 17, 2022
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
MINNEAPOLIS , May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m. , was convened and adjourned, without any business being conducted, due to lack of the required quorum.
May 10, 2022
Nuwellis, Inc. Announces First Quarter 2022 Financial Results
MINNEAPOLIS , May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022 , which included the following highlights: Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the fourth
May 9, 2022
Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of Ultrafiltration for Varying Patient Populations MINNEAPOLIS , May 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc.
April 12, 2022
Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022
MINNEAPOLIS , April 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 . The company will host a conference call and webcast at 9:00 AM ET , during which management will discuss the
Displaying 1 - 10 of 16

Upcoming Events

More events are coming soon.
jump